IDH1 and central nervous system cancer: ,52 The importance of IDH1/2 mutations in glioma is reflected by the fact that, since 2016, they have featured as diagnostic criteria in the World Health Organization’s (WHO) categorization of central nervous system (CNS) tumors.53